The Human Genome Project is completed

Historical milestone — this page describes an event dated 2003. It is not current breaking news.

What was announced on 14 April 2003

The International Human Genome Sequencing Consortium announced that the Human Genome Project was complete. In the United States it was led by the National Human Genome Research Institute and the Department of Energy.

The numbers behind the announcement are worth stating exactly.

The project had been launched in 1990. Congress had been told it would cost about $3 billion in 1991 dollars and finish by the end of 2005. It finished two and a half years early, at $2.7 billion in 1991 dollars.

The finished sequence covers about 99 percent of the human genome's gene-containing regions, at an accuracy of 99.99 percent — fewer than one error per 10,000 letters.

That was a real step up from the working draft announced in June 2000. The draft had covered 90 percent of the gene-containing sequence, only 28 percent of it in finished form, and contained about 150,000 gaps. The finished version left fewer than 400 defined gaps, in regions with unusual structures that could not be reliably read at the time.

Why this mattered for cancer

Cancer is a disease of the genome. Cells acquire changes in their DNA that push them to divide when they should not, ignore signals to stop, and evade repair.

Before 2003, studying those changes meant working gene by gene, with nothing to compare against. The finished sequence supplied that reference. Comparing a tumor's DNA against the same person's normal DNA became a job that could be done.

NHGRI's own measure of the shift is blunt: when the project began in 1990, scientists had found fewer than 100 human disease genes. By 2003, more than 1,400 had been identified.

What was built on top of it

The most direct cancer follow-on was The Cancer Genome Atlas, or TCGA.

NCI describes it as a joint effort with NHGRI that began in 2006. It studied more than 20,000 primary cancer samples, with matched normal samples, across 33 cancer types. Over about a dozen years it produced more than 2.5 petabytes of data, all of it public. Its Pan-Cancer Atlas, published in 2018 as the program closed, looked for themes shared across cancer types.

That is the machinery underneath modern tumor testing. A doctor may order a panel to check a lung tumor for EGFR or ALK changes, a bowel tumor for RAS and HER2 status, or a prostate tumor for BRCA changes. The reference sequence, and the catalogs built on it, are what make those results readable. Our page on biomarker testing and precision medicine covers what those tests do in practice.

Inherited risk testing runs on the same foundation. Knowing what a normal BRCA1 sequence looks like is what makes an abnormal one identifiable. Our page on genetic testing for cancer risk explains who that testing is offered to.

What a genome does not tell you

A reference sequence is a parts list, not an instruction manual.

Knowing the letters did not explain what most of them do, which changes matter, or how to interfere with them. Turning sequence into treatment took another decade and a great deal of work that the 2003 announcement did not itself contain.

"Completed" was also a technical term with edges. Fewer than 400 defined gaps remained in 2003. Regions with repetitive or unusual structure were filled in only by later projects using technology that did not exist then.

And a genome is not a diagnosis. Carrying a variant linked to cancer risk raises the probability of disease; it does not create certainty in either direction.

When to get checked

Genomics changes two practical things for an ordinary reader.

The first is inherited risk. It is worth asking about genetic counseling in several situations. A parent, sibling, or child diagnosed with cancer under 50. Several relatives on one side of the family with linked cancers, such as breast and ovarian, or bowel and womb. A male relative with breast cancer. A relative with two separate primary cancers. Ashkenazi Jewish ancestry alongside a family history of breast or ovarian cancer.

None of those means you carry a gene change. They mean the question is worth asking properly, with a counselor rather than a consumer test.

The second is tumor testing after a diagnosis. Anyone with an advanced solid tumor should ask whether it has been tested for targetable changes, and what came back. That answer can change which treatment comes first.

What this does not mean

Sequencing the genome did not treat anyone. No patient's outcome changed on 14 April 2003.

It also did not deliver the personalized medicine that headlines promised at the time. Progress has been real and uneven. It changed everything for some cancers with clear molecular drivers, and little so far for others.

Nor did it settle what causes cancer. Inherited variants account for a minority of cases. Most cancers come from changes picked up over a lifetime. The sequence helped find those changes; it did not explain everything that produces them.

What it did do is supply the shared reference that everything since has been measured against. That is a smaller claim than the anniversary coverage usually makes, and it is the accurate one.

Sources

• NHGRI: International Consortium Completes Human Genome Project (14 April 2003)
• NCI Center for Cancer Genomics: The Cancer Genome Atlas Program
• NCI: Cancer Statistics

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.